日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Publisher Correction: Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial

出版商更正:突变型 KRAS 疫苗联合双重免疫检查点阻断治疗切除胰腺癌:一项 I 期试验

Huff, Amanda L; Haldar, S Daniel; Girgis, Alexander A; Wang, Hejia Henry; Danilova, Ludmila; Heumann, Thatcher; Berg, Maureen; Wang, Yuxuan; Andaloori, Lalitya; Hernandez, Alexei; Longway, Gabriella; Barrett, Benjamin; Zhu, Zirui; Davis-Marcisak, Emily; Thoburn, Christopher; Leatherman, James; Mitchell, Sarah; Lee, Jae W; Shu, Daniel H; Konig, Maximillian F; Mog, Brian J; Montagne, Janelle; Coyne, Erin M; Bever, Katherine; Baretti, Marina; Yarchoan, Mark; Anders, Robert A; Kagohara, Luciane T; Laheru, Daniel; Thomas, Amy M; Durham, Jennifer; Nauroth, Julie M; Lu, Jiayun; Wang, Hao; Fertig, Elana J; Ho, Won Jin; Azad, Nilofer S; Jaffee, Elizabeth M; Zaidi, Neeha

Mutant KRAS vaccine with dual checkpoint blockade in resected pancreatic cancer: a phase I trial.

突变型 KRAS 疫苗联合双重检查点阻断治疗切除的胰腺癌:一项 I 期试验。

Huff Amanda L, Haldar S Daniel, Gergis Alexander A, Wang Hejia Henry, Danilova Ludmila, Heumann Thatcher, Berg Maureen, Wang Yuxuan, Andaloori Lalitya, Hernandez Alexei, Longway Gabriella, Barrett Benjamin, Zhu Zirui, Davis-Marcisak Emily, Thoburn Christopher, Leatherman James, Mitchell Sarah, Lee Jae W, Shu Daniel H, Konig Maximillian F, Mog Brian J, Montagne Janelle, Coyne Erin M, Bever Katherine, Baretti Marina, Yarchoan Mark, Anders Robert A, Kagohara Luciane T, Laheru Daniel, Thomas Amy M, Durham Jennifer, Nauroth Julie M, Lu Jiayun, Wang Hao, Fertig Elana J, Ho Won Jin, Azad Nilofer S, Jaffee Elizabeth M, Zaidi Neeha

Broadening the gates: Analysis of potentially modifiable study entry criteria in pancreatic and biliary tract cancer trials

拓宽入组门槛:胰腺癌和胆道癌试验中潜在可修改的研究入组标准分析

Saj, Fen; Namayanja, Felicity K; Xiao, Lianchun; Borad, Mitesh J; Kelley, Robin Kate; Goyal, Lipika; Azad, Nilofer S; Bachini, Melinda; Lindsey, Stacie; Pant, Shubham; Valle, Juan W; Fashoyin-Aje, Lola A; Javle, Milind

Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1- mutant cholangiocarcinoma.

肿瘤来源的 CCL2 驱动 IDH1 突变型胆管癌的肿瘤生长和免疫抑制

Zabransky Daniel J, Kartalia Emma, Lee Jae W, Leatherman James M, Charmsaz Soren, Young Sara E, Chhabra Yash, Franch-Expósito SebastiÃ, Kang Martin, Maru Saumya, Rastkari Noushin, Davis Michael, Dalton William Brian, Oshima Kiyoko, Baretti Marina, Azad Nilofer S, Jaffee Elizabeth M, Yarchoan Mark

Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study

肿瘤内注射INT230-6治疗晚期实体瘤成年患者的安全性和有效性:一项开放标签1/2期剂量递增研究的结果

Thomas, Jacob S; Siu, Lillian L; Ingham, Matthew; Azad, Nilofer S; Meyer, Christian F; Olszanski, Anthony J; Whalen, Giles F; Camacho, Luis H; Hu, James S; Hanna, Diana L; Cheng, Phillip M; Abdul Razak, Albiruni R; Abbate, Franco; Mahmood, Syed; Walters, Ian B; Bender, Lewis H; El-Khoueiry, Anthony B

Next-Generation Sequencing-Based MSI Scoring Predicts Benefit in Mismatch Repair-Deficient Tumors Treated with Nivolumab: Follow-up on NCI-MATCH Arm Z1D

基于下一代测序的MSI评分可预测错配修复缺陷型肿瘤患者接受纳武利尤单抗治疗的获益:NCI-MATCH Z1D组随访研究

Schoenfeld, Jonathan D; Azad, Nilofer S; Gross, Jacob; Chen, Li; Overman, Michael J; Kao, Katrina; Jackson, Latifa; Brunnquell, Donna; Bu, Xiangning; Coppola, Christina; Guan, Ping; Lee, Jennifer; Sims, David; Fuchs, Rebecca; Weirather, Jason L; Pfaff, Kathleen L; Gunasti, Lauren; Ranasinghe, Srin; Hamilton, Stanley R; Wang, Victoria; O'Dwyer, Peter J; Wu, Catherine J; Rodig, Scott J; Patton, David R; Harris, Lyndsay

Profiling ADC targets in cholangiocarcinoma: implications for therapeutic development

胆管癌中抗体药物偶联物(ADC)靶点的分析:对治疗研发的启示

Nakazawa, Mari; Arif, Waqar; Baraban, Ezra; Matoso, Andres; Hallab, Elsa; Kartalia, Emma; Azad, Nilofer S; Baretti, Marina; Zabransky, Daniel J; Anders, Robert A; Oshima, Kiyoko; Yarchoan, Mark

Spatial proteomics and transcriptomics reveal early immune cell organization in pancreatic intraepithelial neoplasia.

空间蛋白质组学和转录组学揭示了胰腺上皮内瘤变早期免疫细胞的组织结构

Lyman Melissa R, Mitchell Jacob T, Raghavan Sidharth, Kagohara Luciane T, Huff Amanda L, Haldar Saurav D, Shin Sarah M, Guinn Samantha, Barrett Benjamin, Longway Gabriella, Hernandez Alexei, Coyne Erin M, Yuan Xuan, Andaloori Lalitya, Lai Jiaying, Liu Yun Zhou, Karchin Rachel, Gupta Anuj, Kiemen Ashley L, Forjaz André, Wirtz Denis, Wu Pei-Hsun, Deshpande Atul, Lee Jae W, Armstrong Todd D, Azad Nilofer S, Zimmerman Jacquelyn W, Wood Laura D, Anders Robert A, Thompson Elizabeth D, Jaffee Elizabeth M, Fertig Elana J, Ho Won Jin, Zaidi Neeha

Cancer Susceptibility Gene Testing in Patients With Pancreatic Ductal Adenocarcinoma: Implementation in a Cancer Center Oncology Clinic

胰腺导管腺癌患者的癌症易感基因检测:在癌症中心肿瘤诊所的实施

Sinan, Hassan; Cunningham, Dea; Sleiman, Emy Abou; Petry, Dana; McPhaul, Thomas; Visvanathan, Kala; Armstrong, Deborah K; He, Jin; Burkhart, Richard; Pishvaian, Michael J; Zheng, Lei; Zaidi, Neeha; Azad, Nilofer S; Laheru, Daniel; Goggins, Michael

Olaparib in treatment-refractory isocitrate dehydrogenase 1 (IDH1)- and IDH2-mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial

奥拉帕尼治疗难治性异柠檬酸脱氢酶 1 (IDH1) 和 IDH2 突变型胆管癌:来自美国国家癌症研究所 10129 II 期试验的安全性和抗肿瘤活性

Cecchini, Michael; Pilat, Mary Jo; Uboha, Nataliya; Azad, Nilofer S; Cho, May; Davis, Elizabeth J; Ahnert, Jordi Rodon; Tinoco, Gabriel; Shapiro, Geoffrey I; Khagi, Simon; Powers, Benjamin; Spencer, Kristen; Groisberg, Roman; Drappatz, Jan; Chen, Li; Das, Biswajit; Bao, Xun; Li, Jing; Narayan, Azeet; Vu, Dennis; Patel, Abhijit; Niger, Monica; Doroshow, Deborah; Durecki, Diane; Boerner, Scott A; Bindra, Ranjit; Ivy, Percy; Shyr, Derek; Shyr, Yu; LoRusso, Patricia M